Aesthetic Consultation Workflow: Screening and No-Treatment Decisions

The aesthetic consultation is the highest-risk 30 minutes in a med spa. It is where a practice either identifies the patient whose autoimmune condition contraindicates fillers, the one whose expectations exceed what any treatment can deliver, or the one who should not be treated at all — or it misses all three and proceeds to injection. The American Med Spa Association (AmSpa) recommends that med spas collect medical history before any aesthetic treatment as a standard-of-care requirement. Seventeen states enacted new laws in 2025 about who can work in med spas and how they must be supervised, many of which touch consultation requirements.

This article covers the full consultation workflow: what belongs on the intake form, how to structure contraindication screening, how to manage expectations without turning the consult into a sales presentation, when and how to make the no-treatment decision, and the documentation that makes the consultation defensible.

The Intake Form: Clinical Screening, Not Paperwork

The intake form is a contraindiction screen, a liability record, a consent anchor, and a clinical starting point for treatment planning. Generic form builders miss treatment-specific screening: contraindication checklists for injectables, photo-release documentation, and medical history focused on aesthetic risks such as keloid history and autoimmune conditions. The form should be completed before the consultation, not during it.

Required sections

Patient demographics and emergency contacts. Standard identification, referring provider if any, and an emergency contact. If the practice treats minors (some states allow certain procedures with parental consent), age verification belongs here.

Full medical history. This is the highest-risk section. The checklist must cover:

• Cardiovascular conditions and pacemakers — relevant for radiofrequency and laser treatments. RF devices are contraindicated near implanted electronic devices.
• Autoimmune disorders and current steroid or immunosuppressive use — affects healing, filler safety, and inflammatory risk.
• Seizure history and epilepsy — relevant for devices with flashing light (some IPL systems).
• Active infections, MRSA history, and hepatitis — infection control and injection safety.
• Diabetes — affects wound healing, infection risk, and vascular integrity.
• Bleeding disorders and anticoagulant therapy — increased bruising risk for injectables, relative contraindication for microneedling.
• Herpes simplex history — cold sores or fever blisters are critical for laser resurfacing, microneedling, and lip injections. Prophylactic antivirals may be indicated.
• Cancer history and current chemotherapy or radiation — wound healing and immune status.
• HIV/AIDS status — healing and infection considerations.
• Pregnancy or breastfeeding status — contraindication for most injectables, energy-based devices, and many topical agents.
• Keloid or hypertrophic scarring history — affects candidacy for resurfacing, microneedling, and any procedure that creates controlled injury.

Current medications and supplements. Explicitly ask about NSAIDs, aspirin, fish oil, vitamin E, St. John's Wort, and other supplements that increase bleeding risk. Patients frequently omit supplements they consider benign. A photo-to-medication-list approach — where patients photograph their medication bottles — captures more accurate information than free-text recall.

Allergy screening. Specific to aesthetic products: lidocaine and other local anesthetics (present in most HA fillers), latex (gloves, some device components), eggs (some newer filler formulations), and specific filler ingredients. Also ask about reaction to prior aesthetic treatments.

Previous aesthetic treatments. What, when, by whom, and any complications. A patient who has had filler complications at another practice may present with tissue changes that affect treatment planning. A patient who has received permanent fillers (PMMA, silicone, polyalkylimide) is at higher risk for complications with new injections in the same area.

Treatment-specific consent. A separate consent form for each treatment type (neurotoxins, HA fillers, biostimulators, laser, RF microneedling, chemical peels). Each must include the procedure description, risks and side effects, alternatives including no treatment, limitations of results (no guarantees), pre- and post-care instructions, and confirmation that the patient's questions were answered. A single general consent form does not meet the standard.

HIPAA privacy notice. Federally required. Must be acknowledged in writing.

Photo and video consent. Must specify whether images are for internal records only or for external marketing and social media use. This is a separate HIPAA authorization when used for marketing — see the before-and-after photo consent article for the full framework.

Structuring the Consultation: A Four-Phase Workflow

Phase 1: Review and Triage (5–10 minutes, before patient encounter)

Before you walk into the room, a trained staff member or the provider should:

1. Review the completed intake form for red flags. Auto-flag system: any checked box on the medical history that represents a contraindication or precaution should be highlighted — either electronically in the practice management system or manually on a printed form.
2. Identify which contraindications require provider decision-making. Pregnancy is an absolute contraindication that any staff member can flag. "History of autoimmune disorder currently in remission" requires the provider's clinical judgment.
3. Pull relevant prior records. If the patient is returning, review the last treatment note: products used, volumes, lot numbers, complications, and the patient's reported satisfaction.
4. Prepare treatment-specific consent forms. Based on what the patient is likely requesting, have the relevant consents ready. Do not present consent as a pre-signed form the patient is handed after the decision is already made — consent is a process, not a document.

Phase 2: Clinical Assessment and Contraindication Discussion (10–15 minutes)

This is the clinical core of the consultation. The provider:

1. Confirms the intake history verbally. "I see you noted a history of cold sores. Tell me about the last outbreak." Intake forms underreport; verbal confirmation catches what the form missed.

2. Performs a focused physical examination. For injectable consultations: assess facial anatomy, volume distribution, skin quality, asymmetries, and vascular landmarks. For device consultations: Fitzpatrick skin type, active inflammation, pigmentation patterns, and the specific tissue characteristics relevant to the device.

3. Identifies and discusses contraindications. If a contraindication exists, explain it clearly:

   • Absolute contraindication: the treatment cannot be performed. Document the reason and the discussion. Example: pregnancy and neurotoxins.
   • Relative contraindication: the treatment may proceed with modifications or precautions. Document the risk-benefit discussion. Example: anticoagulant therapy and filler injection — proceed with adjusted technique and heightened bruise management, or defer.
   • Precaution that changes the treatment plan: not a contraindication, but a factor that modifies product selection, injection depth, or device settings. Example: Fitzpatrick IV–VI skin and IPL — adjust fluence, add test spot, or choose a safer wavelength.

4. Assesses for the no-treatment decision. Not every patient who requests a treatment should receive it. The ethical obligation to decline treatment applies when:

   • The patient's desired outcome is not achievable with the requested treatment.
   • The patient's expectations exceed what any treatment can deliver.
   • The risk-benefit profile does not favor treatment for this specific patient.
   • The patient is unable or unwilling to follow post-care instructions that are necessary for safety.

   A patient who requests lip filler to look like a filtered Instagram photo, who has a history of poor follow-up after complications, or who is seeking treatment for body dysmorphic concerns that fillers will not address — these patients may need to be told "not today" or "not this treatment."

Phase 3: Treatment Planning and Expectation Management (10–15 minutes)

If the patient is a candidate for treatment:

1. Present the treatment plan, not just the treatment. Explain what will happen, in what sequence, over what timeline, and what the expected result is — and is not. For GLP-1 patients, multi-session staging may be necessary. For neuromodulator patients, the onset timeline and duration. For device patients, the number of sessions and cumulative improvement model.
2. Use visual references carefully. Before-and-after photos of similar patients (with their consent) are useful for expectation alignment. Do not use filtered, best-case-only images. Show a range of outcomes.
3. Discuss cost transparently. Full treatment cost, including the maintenance schedule. A patient who budgets for one syringe of filler but actually needs three to achieve the discussed outcome is a patient who will feel misled.
4. Obtain informed consent. Consent is a conversation, not a signature. Walk through the consent form with the patient. Answer questions. Modify the treatment plan if the patient declines certain elements. Document that the patient had the opportunity to ask questions and that their questions were answered.
5. Address the "what if" scenarios. What happens if there is a complication? Who does the patient call? What is the practice's complication management protocol? A patient who knows the safety net is in place is more confident in the treatment — and better equipped to seek help promptly if something goes wrong.

Phase 4: The Decision Point — Treat, Defer, or Decline

At the end of the consultation, one of three things happens:

Treat today. The patient is an appropriate candidate, expectations are aligned, consent is documented, and the treatment can proceed.

Defer. The patient may be a candidate, but not today. Reasons include: active infection that needs to resolve, anticoagulant that should be held (with prescribing provider approval), a need for pre-treatment (antiviral prophylaxis, skin preparation), or weight instability in GLP-1 patients that makes volumization premature. Set a specific follow-up date.

Decline. The patient is not a candidate for this treatment, or at this time. Document the clinical rationale, the discussion with the patient, and any alternative recommendations or referrals. A declining decision is not a failure — it is the practice's most important liability protection and patient-safety function.

The No-Treatment Decision: Documentation and Communication

Declining to treat is one of the hardest clinical decisions in aesthetic practice, and one of the most important. Documentation must include:

1. The clinical reason. Specific and defensible: "Patient has active HSV outbreak in the treatment area. Filler injection in the presence of active herpetic lesions increases the risk of disseminated infection. Treatment deferred until outbreak resolves and prophylactic antiviral therapy is established."
2. What was communicated to the patient. "Discussed with patient that treatment cannot proceed today due to active infection. Provided explanation of risk. Patient understood and agreed to return in 10–14 days after resolution."
3. Any alternatives offered. "Discussed neurotoxin treatment of the upper face, which is not contraindicated by the current HSV outbreak. Patient declined and prefers to address all areas at a single visit."
4. The follow-up plan. "Patient instructed to call when outbreak has resolved. Practice will call to confirm in 2 weeks."

A declined treatment that is well-documented protects the practice in two directions: it shows the standard of care was met, and it prevents the patient from claiming they were not informed of a contraindication.

Common Consultation Failures and How to Prevent Them

Failure 1: The intake form is completed post-treatment. The patient fills out the history form after the filler is already injected. This is not screening — it is documentation theater. The intake form must be completed and reviewed before the provider enters the room.

Failure 2: One consent form covers everything. A single "aesthetic treatment consent" does not meet the standard. Each treatment type has a distinct risk profile. Botox consent must address dysphagia, ptosis, and diffusion. Filler consent must address vascular occlusion, Tyndall effect, and the need for hyaluronidase reversal. Laser consent must address PIH, scarring, and eye safety. Use treatment-specific forms.

Failure 3: The consult is a sales pitch. The consultation should be a clinical assessment, not a conversion funnel. If the provider's compensation structure incentivizes treatment over clinical judgment, the consultation is compromised. The safest practices separate the clinical assessment from the financial discussion.

Failure 4: "No treatment" is never discussed as an option. Informed consent must include the alternative of no treatment. If the patient is not a candidate, this is not merely a missed sale — it is a patient-safety failure to proceed.

Failure 5: Poor handoff between screening staff and provider. The front desk flags a contraindication, but the provider does not see it because it is buried in the EMR. Use a visible flagging system — a highlighted field, an alert prompt, or a verbal handoff protocol.

Documentation Standards for the Consultation

AmSpa's practice guidelines (prepared by ByrdAdatto attorneys) and the 2025 state-level regulatory tightening both expect clear documentation for every consultation. The record should include:

• Completed intake form (signed and dated)
• Treatment-specific informed consent (signed and dated after the consent conversation)
• Provider's clinical assessment notes: anatomy, concerns, Fitzpatrick type, relevant medical factors
• Contraindications identified and how they were addressed
• Treatment plan including product, zone, and staged timeline
• The decision made (treat, defer, decline) with clinical rationale
• Photographs if taken (with photo consent)
• Follow-up plan
• Any deviation from standard protocol with documented reasoning

Incomplete charting is one of the most common issues found in medical spa audits. Charting must show not only what service was performed but also who supervised it, who performed it, and what clinical reasoning supported it.

Sources

• American Med Spa Association. Forms, Consents, and SOPs. Updated 2026. Available at: https://www.americanmedspa.org/forms-and-downloads
• American Med Spa Association. Guidelines for Non-Invasive Medical Aesthetic Practices (Medical Spas). September 15, 2020. Available at: https://www.facialesthetics.org/wp-content/uploads/2020/10/amspa_practice_guidelines.pdf
• MedispaCover. What Forms and Consents Are Legally Required for Med Spa Treatments. Available at: https://medispacover.com/medispa-qa/required-forms-and-consents
• Aesthetic Compliance Experts. Med Spa Compliance Guide 2025: Key Regulations and Best Practices. Available at: https://www.aestheticcomplianceexperts.com/post/medspa-compliance-master-the-requirements-for-2025
• Pabau. Medical Spa Client Intake Form: What to Include (2026). Available at: https://pabau.com/blog/medical-spa-client-intake-form
• Business of Aesthetics. How to Protect Your Aesthetic Practice and Avoid Costly Legal Mistakes. September 26, 2025. Available at: https://www.businessofaesthetics.org/blog/aesthetic-practice-legal-compliance-guide
• Phorest. Compliance Checklist for Med Spas in New York: 2026 Edition. Available at: https://www.phorest.com/us/blog/compliance-checklist-for-med-spas-in-new-york-2026-edition
• OptiMantra. Aesthetic Treatment Plan Template: A Guide for Modern Med Spa Practices. March 10, 2026. Available at: https://www.optimantra.com/blog/aesthetic-treatment-plan-template-a-guide-for-modern-med-spa-practices
• PatientNow. Essential Questions to Include on an Intake Form for Med Spas. Available at: https://www.patientnow.com/resources/blog/essential-questions-to-include-on-an-intake-form-for-med-spas